Poor
Partially Aligned
Patient Risk:
Medium
Summary
Most pharmacologic/mechanism and dosing statements align with the provided label excerpts, but multiple statements about pricing/patent status are not supported by the provided FDA prescribing information and therefore are unsupported. Overall alignment is poor due to substantial non-label content.
Category Scores
Accurate Statements
Generic Arimidex is known by its active ingredient anastrozole.
Provided label shows ARIMIDEX contains anastrozole (3; and general identity).
The active ingredient in Arimidex and its generic versions is anastrozole.
ARIMIDEX tablets contain 1 mg anastrozole (3).
Anastrozole is a non-steroidal aromatase inhibitor.
12.1 Mechanism of Action: 'selective non-steroidal aromatase inhibitor.'
Anastrozole is used primarily for the treatment of hormone receptor-positive breast cancer in postmenopausal women.
1.1 and 1.2 and 1.3 indicate use in postmenopausal women with hormone receptor-positive (or hormone receptor-unknown) breast cancer.
Anastrozole works by blocking the aromatase enzyme.
12.1: aromatase inhibitor; mechanism described as lowering estradiol concentrations.
Aromatase is responsible for converting androgens into estrogens in the body.
Label excerpt provided emphasizes aromatase/estradiol lowering; no explicit 'androgens to estrogens' wording was included in supplied excerpts.
By reducing estrogen levels, anastrozole can help slow or stop the growth of estrogen-sensitive breast cancer cells.
12.1 notes lowered estradiol; 14.1 shows improved disease-free survival with ARIMIDEX vs tamoxifen.
The standard recommended dose for anastrozole is 1 mg taken once daily.
2.1: 'one 1 mg tablet taken once a day.'
A 30-day supply (1 mg daily) would be consistent with the label dosing frequency.
2.1 dose is once daily; 30-day supply implies 30 tablets at 1 mg/day, but exact tablet counts/pricing are not in label.
Common side effects of anastrozole include hot flashes, joint pain, fatigue, nausea, and headache.
6: common adverse reactions include hot flashes, arthritis/arthralgia (joint pain), nausea and vomiting, headache; fatigue maps to 'asthenia' in label.
Unsupported Statements
A 30-day supply of generic anastrozole can range from $20 to $50 on average.
FDA prescribing information excerpts provided do not include pricing information.
Without insurance, the price of a month's supply of generic anastrozole may exceed $100.
No pricing or insurance-related cost information is present in the provided FDA label excerpts.
A 30-count prescription of 1 mg anastrozole tablets may cost around $25 at one chain pharmacy and about $45 at another chain for the same prescription.
No pharmacy-specific or comparative pricing information is present in the provided FDA label excerpts.
Online pharmacies or discount programs may offer generic anastrozole in the range of $20 to $30 for a month's supply.
No pricing/retail channel information is present in the provided FDA label excerpts.
Prescription discount cards can reduce the cost of generic anastrozole.
No content about discount cards is present in the provided FDA label excerpts.
Prescription discount cards may bring the price of generic anastrozole to approximately $15 to $30 for a 30-day supply regardless of insurance status.
No pricing/discount card/insurance-independent cost information is present in the provided FDA label excerpts.
Arimidex went generic because its patent protection was lost, allowing generic versions to enter the market.
The provided FDA label excerpts do not discuss patents, patent expiry, or generic entry.
The primary patent for anastrozole expired in the United States in 2007.
No patent timeline information is present in the provided FDA label excerpts.
Subsequent patents for anastrozole have also expired, paving the way for generic competition.
No patent information is present in the provided FDA label excerpts.
Aromatase is responsible for converting androgens into estrogens in the body.
The provided label excerpts do not explicitly state 'androgens into estrogens' (mechanism is described via estradiol lowering but that specific biochemical conversion statement is not in the supplied text).
Less common but more serious side effects of anastrozole can include bone thinning (osteoporosis).
The provided label lists osteoporosis as a common adverse reaction (≥10%) rather than 'less common' or 'more serious'.
Less common but more serious side effects of anastrozole can include an increased risk of blood clots.
The provided label excerpts do not mention 'blood clots' as an adverse reaction/warning/precaution.
Contradictions
Low
AI Statement
Less common but more serious side effects of anastrozole can include bone thinning (osteoporosis).
Label Reference
6: 'Common adverse reactions (≥10%) ... osteoporosis'.
Important Omissions
If discussing risks of bone effects, label recommends considering bone mineral density monitoring (5.2), and does not characterize osteoporosis specifically as 'less common but more serious' in the common adverse reactions section.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported or potentially misleading statements about 'blood clots' and reclassification of osteoporosis frequency could affect perceived safety context. However, core dosing and several common adverse effects align with label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements (pricing, patent/generic entry) are not supported by the provided FDA label excerpts; one safety statement contradicts label frequency classification for osteoporosis; 'blood clots' is unsupported by the provided excerpts.
Suggested Improvement
Remove or clearly qualify non-label content (prices, discount cards, patent status). Align adverse reaction frequency categories with the label (osteoporosis is listed among common adverse reactions) and avoid adding risks (e.g., blood clots) unless supported by the provided prescribing information.